A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 23 Jun 2017 Planned End Date changed from 17 Sep 2018 to 14 Mar 2019.
- 10 Jun 2017 Biomarkers information updated
- 05 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.